Viking Therapeutics (VKTX)
(Real Time Quote from BATS)
$65.24 USD
+0.31 (0.48%)
Updated Apr 24, 2024 03:48 PM ET
After-Market: $65.03 -0.21 (-0.32%) 4:06 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
VKTX 65.24 +0.31(0.48%)
Will VKTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VKTX
Brian Big Idea On Technical Analysis
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
Other News for VKTX
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics options imply 8.8% move in share price post-earnings
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
3 Biotech Stocks With Skyrocketing Potential: April 2024
3 Red-Hot Biotech Rockets Blasting Off in 2024